UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000059440
Receipt number R000067978
Scientific Title Internet Survey on Nutritional Management and Relapse Status in IBD Patients - 3R Survey
Date of disclosure of the study information 2025/10/27
Last modified on 2025/10/17 11:00:24

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Internet Survey on Nutritional Management and Relapse Status in IBD Patients - 3R Survey

Acronym

Internet Survey on Nutritional Management and Relapse Status in IBD Patients - 3R Survey

Scientific Title

Internet Survey on Nutritional Management and Relapse Status in IBD Patients - 3R Survey

Scientific Title:Acronym

Internet Survey on Nutritional Management and Relapse Status in IBD Patients - 3R Survey

Region

Japan


Condition

Condition

Crohn's disease, Ulcerative colitis

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

An online survey of IBD patients will be conducted to assess their nutritional management practices and relapse patterns.

Basic objectives2

Others

Basic objectives -Others

Evaluate the relationship between nutritional management status and recurrence, as well as the usefulness and challenges of nutritional therapy.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Implementation rate of nutritional management and recurrence status, etc.

Key secondary outcomes

Disease, age, gender, height, weight, employment status, smoking status, outpatient visit frequency, duration of illness, surgical history, hospitalization history, severity of symptoms (diarrhea/abdominal pain), current medications, current treatment satisfaction, explanation of nutritional therapy, experience with Elental, current Elental usage (only for those with experience), changes after taking Elental (only for those with experience), duration of Elental use (only for those with experience), Reasons for discontinuing Enteral therapy (only for those with experience), frequency of IBD flare-ups, factors perceived to influence IBD flare-ups, dietary management status, supplement usage status, medication adherence, factors affecting missed doses, IBD health status, and use of nutrition management apps.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Individuals with Crohn's disease or ulcerative colitis who are registered in the Cross Marketing Co., Ltd. survey cooperation panel and who have agreed to participate in this survey

Key exclusion criteria

None

Target sample size

150


Research contact person

Name of lead principal investigator

1st name Takahiro
Middle name
Last name Suzuki

Organization

EA Pharma

Division name

Medical Department, Medical Science Group

Zip code

104-0042

Address

2-1-1 Irifune, Chuo-ku, Tokyo

TEL

080-1060-3254

Email

takahirob_suzuki@eapharma.co.jp


Public contact

Name of contact person

1st name Takahiro
Middle name
Last name Suzuki

Organization

EA Pharma

Division name

Medical Department, Medical Science Group

Zip code

104-0042

Address

2-1-1 Irifune, Chuo-ku, Tokyo

TEL

080-1060-3254

Homepage URL


Email

takahirob_suzuki@eapharma.co.jp


Sponsor or person

Institute

EA Pharma

Institute

Department

Personal name



Funding Source

Organization

EA Pharma

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Yamauchi Clinic Research Ethics Committee

Address

1-15-9 Jiyugaoka, Meguro-ku, Tokyo

Tel

03-6777-1490

Email

c-irb_ug@neues.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2025 Year 10 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2025 Year 10 Month 16 Day

Date of IRB

2025 Year 10 Month 16 Day

Anticipated trial start date

2025 Year 11 Month 04 Day

Last follow-up date

2025 Year 11 Month 28 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

None


Management information

Registered date

2025 Year 10 Month 17 Day

Last modified on

2025 Year 10 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067978